Drugs.com - Clinical Trials

Merck Initiates Phase 3 Study Evaluating V181 Dengue Vaccine Candidate

RAHWAY, N.J.--(BUSINESS WIRE) June 12, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a...

Jun 14, 2025 - 01:40
 0
Merck Initiates Phase 3 Study Evaluating V181 Dengue Vaccine Candidate
RAHWAY, N.J.--(BUSINESS WIRE) June 12, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a...
Read More

Tags:

Previous Article

Johnson & Johnson’s Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Re...

Next Article

Indonesia launches rare crackdown on nickel mines in ‘last paradise’

Related Posts

Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia

Merck Announces Positive Topline Results From the First...

Jun 10, 2025  0

Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea

Apnimed Announces Positive Topline Results in the First...

May 20, 2025  0

Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Presented New Data From Pivotal Phase 3 IMPALA-2...

May 26, 2025  0